Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spanlecortemlocel - Magenta Therapeutics

Drug Profile

Spanlecortemlocel - Magenta Therapeutics

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Magenta Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Inborn error metabolic disorders

Most Recent Events

  • 24 Jun 2020 Magenta Therapeutics completes enrolment in its phase II trial for Inborn error metabolic disorders in USA (unspecified route) (NCT03406962)
  • 11 Jun 2020 Magenta Therapeutics suspends enrolment in a phase II trial in Inborn error metabolic disorder in USA due to enrolment challenges and feedback from the US FDA
  • 21 Feb 2020 Pharmacodynamics results from a preclinical study released by Magenta Therapeutics
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top